Jazz Pharmaceuticals plc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B |
| Selling, general & administrative | $1.8B | $1.4B | $1.3B | $1.4B | $1.5B |
| Research and development | $782.7M | $884.0M | $849.7M | $590.5M | $505.7M |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M |
| Pretax income | -$627.9M | $470.4M | $297.9M | -$372.8M | -$112.8M |
| Income tax expense | -$272.4M | -$91.4M | -$119.9M | -$158.6M | $216.1M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M |
| Balance Sheet | |||||
| Cash and equivalents | $1.4B | $2.4B | $1.5B | $881.5M | $591.4M |
| Current assets | $4.2B | $4.6B | $3.4B | $2.6B | $2.6B |
| Total assets | $11.7B | $12.0B | $11.4B | $10.8B | $12.3B |
| Current liabilities | $2.2B | $1.0B | $1.5B | $933.2M | $809.3M |
| Total debt | $5.4B | $6.2B | $5.8B | $5.8B | $6.4B |
| Stockholders' equity | $4.3B | $4.1B | $3.7B | $3.1B | $4.0B |
| Cash Flow Statement | |||||
| Cash from operations | $1.4B | $1.4B | $1.1B | $1.3B | $778.5M |
| Depreciation and amortization | $41.6M | $32.8M | $30.4M | $30.3M | $26.7M |
| Stock-based compensation | $291.1M | $248.0M | $226.8M | $222.0M | $189.0M |
| Capital expenditure | $58.8M | $38.1M | $24.0M | $29.0M | $27.6M |
| Free cash flow | $1.3B | $1.4B | $1.1B | $1.2B | $750.9M |
| Share repurchases | $125.0M | $311.4M | $269.8M | $54,000 | $0 |
| Impairments | $0 | $0 | $0 | $133.6M | $0 |
Shares outstanding 62.7M · Free float 57.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.